Remus Pharma bets on B2C and GLP-1 after 38% revenue jump
FY26 growth was strong, but the real story is the planned shift toward higher-margin consumer revenue, with B2C targeting 30% of sales.
What's new
- Remus plans to scale B2C to at least 30% of revenue, up from current levels.
- Company entering GLP-1 segment under an asset-light model.
- Geographic expansion into Bolivia, Peru and other markets.
Why this matters
Remus is transitioning from a pure pharmaceutical distribution model to a higher-margin, consumer-facing business. The entry into GLP-1 drugs—a hot category—adds a potential growth engine, though it comes with regulatory and competitive risks. The asset-light approach helps preserve returns, but near-term execution on the B2C ramp remains the open question.
What we're watching
- B2C revenue share trajectory over FY27 quarters.
- GLP-1 product launch timelines and regulatory approvals.
- Margin trends as consumer revenue mix increases.
The full read
Remus Pharmaceuticals delivered 38% revenue growth in FY26, but the concall's focus was firmly on the future. Management laid out a clear pivot: B2C will climb to at least 30% of revenue, up from a much smaller base, and the company is entering the GLP-1 segment on an asset-light footing. Geographic expansion into Bolivia and Peru adds further optionality. The shift to direct-to-consumer and GLP-1 drugs could meaningfully expand margins and diversify revenue beyond traditional distribution. However, the B2C ramp demands investment in marketing and distribution, and the GLP-1 space is crowded and regulatory-intensive. The post-call disclosure means the market had the headline numbers, but the specificity of targets—particularly the 30% B2C share—is new. Execution will determine whether this pivot is a step change or a sidestep.